Company intelligence / Profile preview
Epeius Biotechnologies
San Marino, California, United Statesepeiusbiotech.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Rexin-G has demonstrated significant anti-tumor activity and safety across several refractory cancers. It has achieved FDA Orphan Drug Status and Fast Track Designation for pancreatic cancer, with accelerated approval in the Philippines. Clinical trials have shown efficacy as a single agent with minimal toxicity.
- Therapeutic areas
- HematologyOncology
- Modalities
- Gene therapyNanoparticleViral vector-based gene delivery
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Not specified; company mentions strategic partnerships sought or possible in oncology, immunology, cardiovascular, ocular/wound healing applications.
Beyond the preview
Go deeper on Epeius Biotechnologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Epeius Biotechnologies.